News & Resources


Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the companys North American partner, Takeda Pharmaceuticals. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolongedMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.12 (5.31%)
Oct 08, 2015 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
10/01/15Orexigen Announces Submission of Contrave® New Drug Application in South KoreaPrinter Friendly Version
09/23/15Orexigen Receives Payments Totaling $22 Million from U.S. and Korean PartnersPrinter Friendly Version
09/10/15Orexigen Raises $60 Million in Sale of Common Stock to BaupostPrinter Friendly Version
09/04/15Orexigen Therapeutics to Speak at the Wells Fargo Securities 2015 Healthcare ConferencePrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.